Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects

• Published in: Clinical pharmacokinetics Vol. 61; no. 5; pp. 687 - 695
• Main Authors: Zenklusen, Isabelle, Hsin, Chih-Hsuan, Schilling, Uta, Kankam, Martin, Krause, Andreas, Ufer, Mike, Dingemanse, Jasper
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2022; Springer Nature B.V
• Subjects: Blood clots; Blood platelets; Blood pressure; Confidence intervals; Drug dosages; Heart attacks; Internal Medicine; Medicine; Medicine & Public Health; Metabolism; NCT; NCT04557280; Original Research Article; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Urine

Background and Objectives Selatogrel is a potent, reversible, and selective antagonist of the platelet P2Y 12 receptor currently developed for the treatment of acute myocardial infarction (AMI). In the completed Phase I/II studies, selatogrel was subcutaneously (s.c.) administered as a lyophilizate-...